The global Scleroderma Therapeutics market is projected to grow from US$ 1495 million in 2024 to US$ 1827.1 million by 2030, at a Compound Annual Growth Rate (CAGR) of 3.4% during the forecast period.

Scleroderma Therapeutics Market

Scleroderma is an autoimmune, rheumatic, and chronic disease that affects the body by hardening connective tissue. Therapies include immunosuppressive drugs and, in some cases, glucocorticoids, and it is expected to the development of targeted biologics and small molecule combination therapies.

Market Analysis and Insights: Global Scleroderma Therapeutics Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Covers:

This report presents an overview of global market for Scleroderma Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Scleroderma Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Scleroderma Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Scleroderma Therapeutics revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Scleroderma Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Scleroderma Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Market Segmentation

Scope of Scleroderma Therapeutics Market Report

Report Metric	Details
Report Name	Scleroderma Therapeutics Market
Accounted market size in 2024	US$ 1495 in million
Forecasted market size in 2030	US$ 1827.1 million
CAGR	3.4
Base Year	2024
Forecasted years	2025 - 2030
Segment by Type	Immunosuppressors Phosphodiesterase 5 Inhibitors - PHA Endothelin Receptor Antagonists Prostacyclin Analogues Calcium Channel Blockers Analgesics Others
Segment by Application	Systemic Localized
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Celgene Corporation, Argentis Pharmaceuticals, LLC, Bayer AG, Boehringer Ingelheim International GmbH, Akashi Therapeutics, Prometic Life Sciences, Inc., Emerald Health Pharmaceuticals, Kadmon Holdings, Inc., Seattle Genetics, Inc., Cytori Therapeutics, Inc., Fibrocell Science, Inc., Chemomab, Corbus Pharmaceuticals Holdings, Inc., Genkyotex
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Scleroderma Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Scleroderma Therapeutics companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Scleroderma Therapeutics revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

FAQ for this report

How fast is Scleroderma Therapeutics Market growing?

Ans: The Scleroderma Therapeutics Market witnessing a CAGR of 3.4 during the forecast period 2025-2030.

What is the Scleroderma Therapeutics Market size in 2030?

Ans: The Scleroderma Therapeutics Market size in 2030 will be US$ 1827.1 million.

Who are the main players in the Scleroderma Therapeutics Market report?

Ans: The main players in the Scleroderma Therapeutics Market are F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Celgene Corporation, Argentis Pharmaceuticals, LLC, Bayer AG, Boehringer Ingelheim International GmbH, Akashi Therapeutics, Prometic Life Sciences, Inc., Emerald Health Pharmaceuticals, Kadmon Holdings, Inc., Seattle Genetics, Inc., Cytori Therapeutics, Inc., Fibrocell Science, Inc., Chemomab, Corbus Pharmaceuticals Holdings, Inc., Genkyotex

What are the Application segmentation covered in the Scleroderma Therapeutics Market report?

Ans: The Applications covered in the Scleroderma Therapeutics Market report are Systemic, Localized

What are the Type segmentation covered in the Scleroderma Therapeutics Market report?

Ans: The Types covered in the Scleroderma Therapeutics Market report are Immunosuppressors, Phosphodiesterase 5 Inhibitors - PHA, Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers, Analgesics, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Scleroderma Therapeutics Market Size Growth Rate by Type, 2019 VS 2023 VS 2030

1.2.2 Immunosuppressors

1.2.3 Phosphodiesterase 5 Inhibitors - PHA

1.2.4 Endothelin Receptor Antagonists

1.2.5 Prostacyclin Analogues

1.2.6 Calcium Channel Blockers

1.2.7 Analgesics

1.2.8 Others

1.3 Market by Application

1.3.1 Global Scleroderma Therapeutics Market Size Growth Rate by Application, 2019 VS 2023 VS 2030

1.3.2 Systemic

1.3.3 Localized

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Scleroderma Therapeutics Market Perspective (2019-2030)

2.2 Global Scleroderma Therapeutics Growth Trends by Region

2.2.1 Scleroderma Therapeutics Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Scleroderma Therapeutics Historic Market Size by Region (2019-2024)

2.2.3 Scleroderma Therapeutics Forecasted Market Size by Region (2025-2030)

2.3 Scleroderma Therapeutics Market Dynamics

2.3.1 Scleroderma Therapeutics Industry Trends

2.3.2 Scleroderma Therapeutics Market Drivers

2.3.3 Scleroderma Therapeutics Market Challenges

2.3.4 Scleroderma Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Revenue Scleroderma Therapeutics by Players

3.1.1 Global Scleroderma Therapeutics Revenue by Players (2019-2024)

3.1.2 Global Scleroderma Therapeutics Revenue Market Share by Players (2019-2024)

3.2 Global Scleroderma Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players of Scleroderma Therapeutics, Ranking by Revenue, 2022 VS 2023 VS 2024

3.4 Global Scleroderma Therapeutics Market Concentration Ratio

3.4.1 Global Scleroderma Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Scleroderma Therapeutics Revenue in 2023

3.5 Global Key Players of Scleroderma Therapeutics Head office and Area Served

3.6 Global Key Players of Scleroderma Therapeutics, Product and Application

3.7 Global Key Players of Scleroderma Therapeutics, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Scleroderma Therapeutics Breakdown Data by Type

4.1 Global Scleroderma Therapeutics Historic Market Size by Type (2019-2024)

4.2 Global Scleroderma Therapeutics Forecasted Market Size by Type (2025-2030)

5 Scleroderma Therapeutics Breakdown Data by Application

5.1 Global Scleroderma Therapeutics Historic Market Size by Application (2019-2024)

5.2 Global Scleroderma Therapeutics Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Scleroderma Therapeutics Market Size (2019-2030)

6.2 North America Scleroderma Therapeutics Market Size by Type

6.2.1 North America Scleroderma Therapeutics Market Size by Type (2019-2024)

6.2.2 North America Scleroderma Therapeutics Market Size by Type (2025-2030)

6.2.3 North America Scleroderma Therapeutics Market Share by Type (2019-2030)

6.3 North America Scleroderma Therapeutics Market Size by Application

6.3.1 North America Scleroderma Therapeutics Market Size by Application (2019-2024)

6.3.2 North America Scleroderma Therapeutics Market Size by Application (2025-2030)

6.3.3 North America Scleroderma Therapeutics Market Share by Application (2019-2030)

6.4 North America Scleroderma Therapeutics Market Size by Country

6.4.1 North America Scleroderma Therapeutics Market Size by Country: 2019 VS 2023 VS 2030

6.4.2 North America Scleroderma Therapeutics Market Size by Country (2019-2024)

6.4.3 North America Scleroderma Therapeutics Market Size by Country (2025-2030)

6.4.4 U.S.

6.4.5 Canada

7 Europe

7.1 Europe Scleroderma Therapeutics Market Size (2019-2030)

7.2 Europe Scleroderma Therapeutics Market Size by Type

7.2.1 Europe Scleroderma Therapeutics Market Size by Type (2019-2024)

7.2.2 Europe Scleroderma Therapeutics Market Size by Type (2025-2030)

7.2.3 Europe Scleroderma Therapeutics Market Share by Type (2019-2030)

7.3 Europe Scleroderma Therapeutics Market Size by Application

7.3.1 Europe Scleroderma Therapeutics Market Size by Application (2019-2024)

7.3.2 Europe Scleroderma Therapeutics Market Size by Application (2025-2030)

7.3.3 Europe Scleroderma Therapeutics Market Share by Application (2019-2030)

7.4 Europe Scleroderma Therapeutics Market Size by Country

7.4.1 Europe Scleroderma Therapeutics Market Size by Country: 2019 VS 2023 VS 2030

7.4.2 Europe Scleroderma Therapeutics Market Size by Country (2019-2024)

7.4.3 Europe Scleroderma Therapeutics Market Size by Country (2025-2030)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

8 China

8.1 China Scleroderma Therapeutics Market Size (2019-2030)

8.2 China Scleroderma Therapeutics Market Size by Type

8.2.1 China Scleroderma Therapeutics Market Size by Type (2019-2024)

8.2.2 China Scleroderma Therapeutics Market Size by Type (2025-2030)

8.2.3 China Scleroderma Therapeutics Market Share by Type (2019-2030)

8.3 China Scleroderma Therapeutics Market Size by Application

8.3.1 China Scleroderma Therapeutics Market Size by Application (2019-2024)

8.3.2 China Scleroderma Therapeutics Market Size by Application (2025-2030)

8.3.3 China Scleroderma Therapeutics Market Share by Application (2019-2030)

9 Asia (excluding China)

9.1 Asia Scleroderma Therapeutics Market Size (2019-2030)

9.2 Asia Scleroderma Therapeutics Market Size by Type

9.2.1 Asia Scleroderma Therapeutics Market Size by Type (2019-2024)

9.2.2 Asia Scleroderma Therapeutics Market Size by Type (2025-2030)

9.2.3 Asia Scleroderma Therapeutics Market Share by Type (2019-2030)

9.3 Asia Scleroderma Therapeutics Market Size by Application

9.3.1 Asia Scleroderma Therapeutics Market Size by Application (2019-2024)

9.3.2 Asia Scleroderma Therapeutics Market Size by Application (2025-2030)

9.3.3 Asia Scleroderma Therapeutics Market Share by Application (2019-2030)

9.4 Asia Scleroderma Therapeutics Market Size by Region

9.4.1 Asia Scleroderma Therapeutics Market Size by Region: 2019 VS 2023 VS 2030

9.4.2 Asia Scleroderma Therapeutics Market Size by Region (2019-2024)

9.4.3 Asia Scleroderma Therapeutics Market Size by Region (2025-2030)

9.4.4 Japan

9.4.5 South Korea

9.4.6 China Taiwan

9.4.7 Southeast Asia

9.4.8 India

9.4.9 Australia

10 Middle East, Africa, and Latin America

10.1 Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size (2019-2030)

10.2 Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size by Type

10.2.1 Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size by Type (2019-2024)

10.2.2 Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size by Type (2025-2030)

10.2.3 Middle East, Africa, and Latin America Scleroderma Therapeutics Market Share by Type (2019-2030)

10.3 Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size by Application

10.3.1 Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size by Application (2019-2024)

10.3.2 Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size by Application (2025-2030)

10.3.3 Middle East, Africa, and Latin America Scleroderma Therapeutics Market Share by Application (2019-2030)

10.4 Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size by Country

10.4.1 Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size by Country: 2019 VS 2023 VS 2030

10.4.2 Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size by Country (2019-2024)

10.4.3 Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size by Country (2025-2030)

10.4.4 Brazil

10.4.5 Mexico

10.4.6 Turkey

10.4.7 Saudi Arabia

10.4.8 Israel

10.4.9 GCC Countries

11 Key Players Profiles

11.1 F. Hoffmann-La Roche AG

11.1.1 F. Hoffmann-La Roche AG Company Details

11.1.2 F. Hoffmann-La Roche AG Business Overview

11.1.3 F. Hoffmann-La Roche AG Scleroderma Therapeutics Introduction

11.1.4 F. Hoffmann-La Roche AG Revenue in Scleroderma Therapeutics Business (2019-2024)

11.1.5 F. Hoffmann-La Roche AG Recent Developments

11.2 Bristol-Myers Squibb Company

11.2.1 Bristol-Myers Squibb Company Company Details

11.2.2 Bristol-Myers Squibb Company Business Overview

11.2.3 Bristol-Myers Squibb Company Scleroderma Therapeutics Introduction

11.2.4 Bristol-Myers Squibb Company Revenue in Scleroderma Therapeutics Business (2019-2024)

11.2.5 Bristol-Myers Squibb Company Recent Developments

11.3 Celgene Corporation

11.3.1 Celgene Corporation Company Details

11.3.2 Celgene Corporation Business Overview

11.3.3 Celgene Corporation Scleroderma Therapeutics Introduction

11.3.4 Celgene Corporation Revenue in Scleroderma Therapeutics Business (2019-2024)

11.3.5 Celgene Corporation Recent Developments

11.4 Argentis Pharmaceuticals, LLC

11.4.1 Argentis Pharmaceuticals, LLC Company Details

11.4.2 Argentis Pharmaceuticals, LLC Business Overview

11.4.3 Argentis Pharmaceuticals, LLC Scleroderma Therapeutics Introduction

11.4.4 Argentis Pharmaceuticals, LLC Revenue in Scleroderma Therapeutics Business (2019-2024)

11.4.5 Argentis Pharmaceuticals, LLC Recent Developments

11.5 Bayer AG

11.5.1 Bayer AG Company Details

11.5.2 Bayer AG Business Overview

11.5.3 Bayer AG Scleroderma Therapeutics Introduction

11.5.4 Bayer AG Revenue in Scleroderma Therapeutics Business (2019-2024)

11.5.5 Bayer AG Recent Developments

11.6 Boehringer Ingelheim International GmbH

11.6.1 Boehringer Ingelheim International GmbH Company Details

11.6.2 Boehringer Ingelheim International GmbH Business Overview

11.6.3 Boehringer Ingelheim International GmbH Scleroderma Therapeutics Introduction

11.6.4 Boehringer Ingelheim International GmbH Revenue in Scleroderma Therapeutics Business (2019-2024)

11.6.5 Boehringer Ingelheim International GmbH Recent Developments

11.7 Akashi Therapeutics

11.7.1 Akashi Therapeutics Company Details

11.7.2 Akashi Therapeutics Business Overview

11.7.3 Akashi Therapeutics Scleroderma Therapeutics Introduction

11.7.4 Akashi Therapeutics Revenue in Scleroderma Therapeutics Business (2019-2024)

11.7.5 Akashi Therapeutics Recent Developments

11.8 Prometic Life Sciences, Inc.

11.8.1 Prometic Life Sciences, Inc. Company Details

11.8.2 Prometic Life Sciences, Inc. Business Overview

11.8.3 Prometic Life Sciences, Inc. Scleroderma Therapeutics Introduction

11.8.4 Prometic Life Sciences, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024)

11.8.5 Prometic Life Sciences, Inc. Recent Developments

11.9 Emerald Health Pharmaceuticals

11.9.1 Emerald Health Pharmaceuticals Company Details

11.9.2 Emerald Health Pharmaceuticals Business Overview

11.9.3 Emerald Health Pharmaceuticals Scleroderma Therapeutics Introduction

11.9.4 Emerald Health Pharmaceuticals Revenue in Scleroderma Therapeutics Business (2019-2024)

11.9.5 Emerald Health Pharmaceuticals Recent Developments

11.10 Kadmon Holdings, Inc.

11.10.1 Kadmon Holdings, Inc. Company Details

11.10.2 Kadmon Holdings, Inc. Business Overview

11.10.3 Kadmon Holdings, Inc. Scleroderma Therapeutics Introduction

11.10.4 Kadmon Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024)

11.10.5 Kadmon Holdings, Inc. Recent Developments

11.11 Seattle Genetics, Inc.

11.11.1 Seattle Genetics, Inc. Company Details

11.11.2 Seattle Genetics, Inc. Business Overview

11.11.3 Seattle Genetics, Inc. Scleroderma Therapeutics Introduction

11.11.4 Seattle Genetics, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024)

11.11.5 Seattle Genetics, Inc. Recent Developments

11.12 Cytori Therapeutics, Inc.

11.12.1 Cytori Therapeutics, Inc. Company Details

11.12.2 Cytori Therapeutics, Inc. Business Overview

11.12.3 Cytori Therapeutics, Inc. Scleroderma Therapeutics Introduction

11.12.4 Cytori Therapeutics, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024)

11.12.5 Cytori Therapeutics, Inc. Recent Developments

11.13 Fibrocell Science, Inc.

11.13.1 Fibrocell Science, Inc. Company Details

11.13.2 Fibrocell Science, Inc. Business Overview

11.13.3 Fibrocell Science, Inc. Scleroderma Therapeutics Introduction

11.13.4 Fibrocell Science, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024)

11.13.5 Fibrocell Science, Inc. Recent Developments

11.14 Chemomab

11.14.1 Chemomab Company Details

11.14.2 Chemomab Business Overview

11.14.3 Chemomab Scleroderma Therapeutics Introduction

11.14.4 Chemomab Revenue in Scleroderma Therapeutics Business (2019-2024)

11.14.5 Chemomab Recent Developments

11.15 Corbus Pharmaceuticals Holdings, Inc.

11.15.1 Corbus Pharmaceuticals Holdings, Inc. Company Details

11.15.2 Corbus Pharmaceuticals Holdings, Inc. Business Overview

11.15.3 Corbus Pharmaceuticals Holdings, Inc. Scleroderma Therapeutics Introduction

11.15.4 Corbus Pharmaceuticals Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024)

11.15.5 Corbus Pharmaceuticals Holdings, Inc. Recent Developments

11.16 Genkyotex

11.16.1 Genkyotex Company Details

11.16.2 Genkyotex Business Overview

11.16.3 Genkyotex Scleroderma Therapeutics Introduction

11.16.4 Genkyotex Revenue in Scleroderma Therapeutics Business (2019-2024)

11.16.5 Genkyotex Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

F. Hoffmann-La Roche AG

Bristol Myers Squibb Company

Celgene Corporation

Argentis Pharmaceuticals, LLC

Bayer

Boehringer Ingelheim International GmbH

Akashi Therapeutics

ProMetic Life Sciences Inc

Emerald Health Pharmaceuticals

Kadmon Holdings, Inc.

Seattle Genetics Inc

Cytori Therapeutics Inc

Fibrocell Science, Inc.

Chemomab

Corbus Pharmaceuticals Holdings, Inc.

Genkyotex

List of Tables

Table 1. Global Scleroderma Therapeutics Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030

Table 2. Key Players of Immunosuppressors

Table 3. Key Players of Phosphodiesterase 5 Inhibitors - PHA

Table 4. Key Players of Endothelin Receptor Antagonists

Table 5. Key Players of Prostacyclin Analogues

Table 6. Key Players of Calcium Channel Blockers

Table 7. Key Players of Analgesics

Table 8. Key Players of Others

Table 9. Global Scleroderma Therapeutics Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030

Table 10. Global Scleroderma Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 11. Global Scleroderma Therapeutics Market Size by Region (2019-2024) & (US$ Million)

Table 12. Global Scleroderma Therapeutics Market Share by Region (2019-2024)

Table 13. Global Scleroderma Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 14. Global Scleroderma Therapeutics Market Share by Region (2025-2030)

Table 15. Scleroderma Therapeutics Market Trends

Table 16. Scleroderma Therapeutics Market Drivers

Table 17. Scleroderma Therapeutics Market Challenges

Table 18. Scleroderma Therapeutics Market Restraints

Table 19. Global Scleroderma Therapeutics Revenue by Players (2019-2024) & (US$ Million)

Table 20. Global Scleroderma Therapeutics Revenue Share by Players (2019-2024)

Table 21. Global Top Scleroderma Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Scleroderma Therapeutics as of 2023)

Table 22. Global Scleroderma Therapeutics Industry Ranking 2022 VS 2023 VS 2024

Table 23. Global 5 Largest Players Market Share by Scleroderma Therapeutics Revenue (CR5 and HHI) & (2019-2024)

Table 24. Global Key Players of Scleroderma Therapeutics, Headquarters and Area Served

Table 25. Global Key Players of Scleroderma Therapeutics, Product and Application

Table 26. Global Key Players of Scleroderma Therapeutics, Product and Application

Table 27. Mergers & Acquisitions, Expansion Plans

Table 28. Global Scleroderma Therapeutics Market Size by Type (2019-2024) & (US$ Million)

Table 29. Global Scleroderma Therapeutics Revenue Market Share by Type (2019-2024)

Table 30. Global Scleroderma Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 31. Global Scleroderma Therapeutics Revenue Market Share by Type (2025-2030)

Table 32. Global Scleroderma Therapeutics Market Size by Application (2019-2024) & (US$ Million)

Table 33. Global Scleroderma Therapeutics Revenue Share by Application (2019-2024)

Table 34. Global Scleroderma Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 35. Global Scleroderma Therapeutics Revenue Share by Application (2025-2030)

Table 36. North America Scleroderma Therapeutics Market Size by Type (2019-2024) & (US$ Million)

Table 37. North America Scleroderma Therapeutics Market Size by Type (2025-2030) & (US$ Million)

Table 38. North America Scleroderma Therapeutics Market Size by Application (2019-2024) & (US$ Million)

Table 39. North America Scleroderma Therapeutics Market Size by Application (2025-2030) & (US$ Million)

Table 40. North America Scleroderma Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 41. North America Scleroderma Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 42. North America Scleroderma Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 43. Europe Scleroderma Therapeutics Market Size by Type (2019-2024) & (US$ Million)

Table 44. Europe Scleroderma Therapeutics Market Size by Type (2025-2030) & (US$ Million)

Table 45. Europe Scleroderma Therapeutics Market Size by Application (2019-2024) & (US$ Million)

Table 46. Europe Scleroderma Therapeutics Market Size by Application (2025-2030) & (US$ Million)

Table 47. Europe Scleroderma Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 48. Europe Scleroderma Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 49. Europe Scleroderma Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 50. China Scleroderma Therapeutics Market Size by Type (2019-2024) & (US$ Million)

Table 51. China Scleroderma Therapeutics Market Size by Type (2025-2030) & (US$ Million)

Table 52. China Scleroderma Therapeutics Market Size by Application (2019-2024) & (US$ Million)

Table 53. China Scleroderma Therapeutics Market Size by Application (2025-2030) & (US$ Million)

Table 54. Asia Scleroderma Therapeutics Market Size by Type (2019-2024) & (US$ Million)

Table 55. Asia Scleroderma Therapeutics Market Size by Type (2025-2030) & (US$ Million)

Table 56. Asia Scleroderma Therapeutics Market Size by Application (2019-2024) & (US$ Million)

Table 57. Asia Scleroderma Therapeutics Market Size by Application (2025-2030) & (US$ Million)

Table 58. Asia Scleroderma Therapeutics Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 59. Asia Scleroderma Therapeutics Market Size by Region (2019-2024) & (US$ Million)

Table 60. Asia Scleroderma Therapeutics Market Size by Region (2025-2030) & (US$ Million)

Table 61. Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size by Type (2019-2024) & (US$ Million)

Table 62. Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size by Type (2025-2030) & (US$ Million)

Table 63. Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size by Application (2019-2024) & (US$ Million)

Table 64. Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size by Application (2025-2030) & (US$ Million)

Table 65. Middle East, Africa, and Latin America Scleroderma Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 66. Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 67. Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 68. F. Hoffmann-La Roche AG Company Details

Table 69. F. Hoffmann-La Roche AG Business Overview

Table 70. F. Hoffmann-La Roche AG Scleroderma Therapeutics Product

Table 71. F. Hoffmann-La Roche AG Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 72. F. Hoffmann-La Roche AG Recent Developments

Table 73. Bristol-Myers Squibb Company Company Details

Table 74. Bristol-Myers Squibb Company Business Overview

Table 75. Bristol-Myers Squibb Company Scleroderma Therapeutics Product

Table 76. Bristol-Myers Squibb Company Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 77. Bristol-Myers Squibb Company Recent Developments

Table 78. Celgene Corporation Company Details

Table 79. Celgene Corporation Business Overview

Table 80. Celgene Corporation Scleroderma Therapeutics Product

Table 81. Celgene Corporation Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 82. Celgene Corporation Recent Developments

Table 83. Argentis Pharmaceuticals, LLC Company Details

Table 84. Argentis Pharmaceuticals, LLC Business Overview

Table 85. Argentis Pharmaceuticals, LLC Scleroderma Therapeutics Product

Table 86. Argentis Pharmaceuticals, LLC Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 87. Argentis Pharmaceuticals, LLC Recent Developments

Table 88. Bayer AG Company Details

Table 89. Bayer AG Business Overview

Table 90. Bayer AG Scleroderma Therapeutics Product

Table 91. Bayer AG Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 92. Bayer AG Recent Developments

Table 93. Boehringer Ingelheim International GmbH Company Details

Table 94. Boehringer Ingelheim International GmbH Business Overview

Table 95. Boehringer Ingelheim International GmbH Scleroderma Therapeutics Product

Table 96. Boehringer Ingelheim International GmbH Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 97. Boehringer Ingelheim International GmbH Recent Developments

Table 98. Akashi Therapeutics Company Details

Table 99. Akashi Therapeutics Business Overview

Table 100. Akashi Therapeutics Scleroderma Therapeutics Product

Table 101. Akashi Therapeutics Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 102. Akashi Therapeutics Recent Developments

Table 103. Prometic Life Sciences, Inc. Company Details

Table 104. Prometic Life Sciences, Inc. Business Overview

Table 105. Prometic Life Sciences, Inc. Scleroderma Therapeutics Product

Table 106. Prometic Life Sciences, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 107. Prometic Life Sciences, Inc. Recent Developments

Table 108. Emerald Health Pharmaceuticals Company Details

Table 109. Emerald Health Pharmaceuticals Business Overview

Table 110. Emerald Health Pharmaceuticals Scleroderma Therapeutics Product

Table 111. Emerald Health Pharmaceuticals Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 112. Emerald Health Pharmaceuticals Recent Developments

Table 113. Kadmon Holdings, Inc. Company Details

Table 114. Kadmon Holdings, Inc. Business Overview

Table 115. Kadmon Holdings, Inc. Scleroderma Therapeutics Product

Table 116. Kadmon Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 117. Kadmon Holdings, Inc. Recent Developments

Table 118. Seattle Genetics, Inc. Company Details

Table 119. Seattle Genetics, Inc. Business Overview

Table 120. Seattle Genetics, Inc. Scleroderma Therapeutics Product

Table 121. Seattle Genetics, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 122. Seattle Genetics, Inc. Recent Developments

Table 123. Cytori Therapeutics, Inc. Company Details

Table 124. Cytori Therapeutics, Inc. Business Overview

Table 125. Cytori Therapeutics, Inc. Scleroderma Therapeutics Product

Table 126. Cytori Therapeutics, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 127. Cytori Therapeutics, Inc. Recent Developments

Table 128. Fibrocell Science, Inc. Company Details

Table 129. Fibrocell Science, Inc. Business Overview

Table 130. Fibrocell Science, Inc. Scleroderma Therapeutics Product

Table 131. Fibrocell Science, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 132. Fibrocell Science, Inc. Recent Developments

Table 133. Chemomab Company Details

Table 134. Chemomab Business Overview

Table 135. Chemomab Scleroderma Therapeutics Product

Table 136. Chemomab Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 137. Chemomab Recent Developments

Table 138. Corbus Pharmaceuticals Holdings, Inc. Company Details

Table 139. Corbus Pharmaceuticals Holdings, Inc. Business Overview

Table 140. Corbus Pharmaceuticals Holdings, Inc. Scleroderma Therapeutics Product

Table 141. Corbus Pharmaceuticals Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 142. Corbus Pharmaceuticals Holdings, Inc. Recent Developments

Table 143. Genkyotex Company Details

Table 144. Genkyotex Business Overview

Table 145. Genkyotex Scleroderma Therapeutics Product

Table 146. Genkyotex Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 147. Genkyotex Recent Developments

Table 148. Research Programs/Design for This Report

Table 149. Key Data Information from Secondary Sources

Table 150. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Scleroderma Therapeutics Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)

Figure 2. Global Scleroderma Therapeutics Market Share by Type: 2023 VS 2030

Figure 3. Immunosuppressors Features

Figure 4. Phosphodiesterase 5 Inhibitors - PHA Features

Figure 5. Endothelin Receptor Antagonists Features

Figure 6. Prostacyclin Analogues Features

Figure 7. Calcium Channel Blockers Features

Figure 8. Analgesics Features

Figure 9. Others Features

Figure 10. Global Scleroderma Therapeutics Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)

Figure 11. Global Scleroderma Therapeutics Market Share by Application: 2023 VS 2030

Figure 12. Systemic Case Studies

Figure 13. Localized Case Studies

Figure 14. Scleroderma Therapeutics Report Years Considered

Figure 15. Global Scleroderma Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 16. Global Scleroderma Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 17. Global Scleroderma Therapeutics Market Share by Region: 2023 VS 2030

Figure 18. Global Scleroderma Therapeutics Market Share by Players in 2023

Figure 19. Global Top Scleroderma Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Scleroderma Therapeutics as of 2023)

Figure 20. The Top 10 and 5 Players Market Share by Scleroderma Therapeutics Revenue in 2023

Figure 21. North America Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. North America Scleroderma Therapeutics Market Share by Type (2019-2030)

Figure 23. North America Scleroderma Therapeutics Market Share by Application (2019-2030)

Figure 24. North America Scleroderma Therapeutics Market Share by Country (2019-2030)

Figure 25. United States Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Canada Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Europe Scleroderma Therapeutics Market Size YoY (2019-2030) & (US$ Million)

Figure 28. Europe Scleroderma Therapeutics Market Share by Type (2019-2030)

Figure 29. Europe Scleroderma Therapeutics Market Share by Application (2019-2030)

Figure 30. Europe Scleroderma Therapeutics Market Share by Country (2019-2030)

Figure 31. Germany Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. France Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. U.K. Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Italy Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Russia Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Nordic Countries Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. China Scleroderma Therapeutics Market Size YoY (2019-2030) & (US$ Million)

Figure 38. China Scleroderma Therapeutics Market Share by Type (2019-2030)

Figure 39. China Scleroderma Therapeutics Market Share by Application (2019-2030)

Figure 40. Asia Scleroderma Therapeutics Market Size YoY (2019-2030) & (US$ Million)

Figure 41. Asia Scleroderma Therapeutics Market Share by Type (2019-2030)

Figure 42. Asia Scleroderma Therapeutics Market Share by Application (2019-2030)

Figure 43. Asia Scleroderma Therapeutics Market Share by Region (2019-2030)

Figure 44. Japan Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. South Korea Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. China Taiwan Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Southeast Asia Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. India Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 49. Australia Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 50. Middle East, Africa, and Latin America Scleroderma Therapeutics Market Size YoY (2019-2030) & (US$ Million)

Figure 51. Middle East, Africa, and Latin America Scleroderma Therapeutics Market Share by Type (2019-2030)

Figure 52. Middle East, Africa, and Latin America Scleroderma Therapeutics Market Share by Application (2019-2030)

Figure 53. Middle East, Africa, and Latin America Scleroderma Therapeutics Market Share by Country (2019-2030)

Figure 54. Brazil Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 55. Mexico Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 56. Turkey Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 57. Saudi Arabia Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 58. Israel Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 59. GCC Countries Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 60. F. Hoffmann-La Roche AG Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 61. Bristol-Myers Squibb Company Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 62. Celgene Corporation Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 63. Argentis Pharmaceuticals, LLC Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 64. Bayer AG Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 65. Boehringer Ingelheim International GmbH Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 66. Akashi Therapeutics Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 67. Prometic Life Sciences, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 68. Emerald Health Pharmaceuticals Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 69. Kadmon Holdings, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 70. Seattle Genetics, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 71. Cytori Therapeutics, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 72. Fibrocell Science, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 73. Chemomab Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 74. Corbus Pharmaceuticals Holdings, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 75. Genkyotex Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 76. Bottom-up and Top-down Approaches for This Report

Figure 77. Data Triangulation

Figure 78. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions